199 related articles for article (PubMed ID: 38478332)
1. Cancer Stem Cells: Current Challenges and Future Perspectives.
Shaikh MV; Custers S; Anand A; Miletic P; Venugopal C; Singh SK
Methods Mol Biol; 2024; 2777():1-18. PubMed ID: 38478332
[TBL] [Abstract][Full Text] [Related]
2. Stem cell programs in cancer initiation, progression, and therapy resistance.
Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
[TBL] [Abstract][Full Text] [Related]
3. Human non-small cell lung cancer expresses putative cancer stem cell markers and exhibits the transcriptomic profile of multipotent cells.
Zakaria N; Yusoff NM; Zakaria Z; Lim MN; Baharuddin PJ; Fakiruddin KS; Yahaya B
BMC Cancer; 2015 Feb; 15():84. PubMed ID: 25881239
[TBL] [Abstract][Full Text] [Related]
4. Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis.
Marquardt S; Solanki M; Spitschak A; Vera J; Pützer BM
Semin Cancer Biol; 2018 Dec; 53():90-109. PubMed ID: 29966677
[TBL] [Abstract][Full Text] [Related]
5. Introduction to Cancer Stem Cells: Past, Present, and Future.
Bakhshinyan D; Adile AA; Qazi MA; Singh M; Kameda-Smith MM; Yelle N; Chokshi C; Venugopal C; Singh SK
Methods Mol Biol; 2018; 1692():1-16. PubMed ID: 28986882
[TBL] [Abstract][Full Text] [Related]
6. Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.
Walcher L; Kistenmacher AK; Suo H; Kitte R; Dluczek S; Strauß A; Blaudszun AR; Yevsa T; Fricke S; Kossatz-Boehlert U
Front Immunol; 2020; 11():1280. PubMed ID: 32849491
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the minimal residual disease state reveals distinct evolutionary trajectories of human glioblastoma.
Qazi MA; Salim SK; Brown KR; Mikolajewicz N; Savage N; Han H; Subapanditha MK; Bakhshinyan D; Nixon A; Vora P; Desmond K; Chokshi C; Singh M; Khoo A; Macklin A; Khan S; Tatari N; Winegarden N; Richards L; Pugh T; Bock N; Mansouri A; Venugopal C; Kislinger T; Goyal S; Moffat J; Singh SK
Cell Rep; 2022 Sep; 40(13):111420. PubMed ID: 36170831
[TBL] [Abstract][Full Text] [Related]
8. CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity.
Joung J; Kirchgatterer PC; Singh A; Cho JH; Nety SP; Larson RC; Macrae RK; Deasy R; Tseng YY; Maus MV; Zhang F
Nat Commun; 2022 Mar; 13(1):1606. PubMed ID: 35338135
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer.
Zhang K; Erkan EP; Jamalzadeh S; Dai J; Andersson N; Kaipio K; Lamminen T; Mansuri N; Huhtinen K; Carpén O; Hietanen S; Oikkonen J; Hynninen J; Virtanen A; Häkkinen A; Hautaniemi S; Vähärautio A
Sci Adv; 2022 Feb; 8(8):eabm1831. PubMed ID: 35196078
[TBL] [Abstract][Full Text] [Related]
10. A Combinatorial CRISPR-Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment.
Xu F; Tong M; Tong CSW; Chan BKC; Chu HY; Wong TL; Fong JHC; Cheung MSH; Mak KH; Pardeshi L; Huang Y; Wong KH; Choi GCG; Ma S; Wong ASL
Cancer Res; 2021 Dec; 81(24):6219-6232. PubMed ID: 34666996
[TBL] [Abstract][Full Text] [Related]
11. CRISPR screens identify cholesterol biosynthesis as a therapeutic target on stemness and drug resistance of colon cancer.
Gao S; Soares F; Wang S; Wong CC; Chen H; Yang Z; Liu W; Go MYY; Ahmed M; Zeng Y; O'Brien CA; Sung JJY; He HH; Yu J
Oncogene; 2021 Dec; 40(48):6601-6613. PubMed ID: 34621019
[TBL] [Abstract][Full Text] [Related]
12. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition.
Ramaker RC; Hardigan AA; Gordon ER; Wright CA; Myers RM; Cooper SJ
BMC Cancer; 2021 May; 21(1):632. PubMed ID: 34049503
[TBL] [Abstract][Full Text] [Related]
13. Single-cell RNA sequencing in cancer: Applications, advances, and emerging challenges.
Sun G; Li Z; Rong D; Zhang H; Shi X; Yang W; Zheng W; Sun G; Wu F; Cao H; Tang W; Sun Y
Mol Ther Oncolytics; 2021 Jun; 21():183-206. PubMed ID: 34027052
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
